•
Mar 31, 2023

Natera Q1 2023 Earnings Report

Natera reported an increase in revenue driven by test volume growth and advancements in women's health and oncology settings.

Key Takeaways

Natera reported a 24.5% increase in total revenue to $241.8 million, driven by a 25.2% increase in product revenue due to higher test volumes. The company processed approximately 626,200 tests, with a net loss of $136.9 million, or ($1.23) per diluted share.

Total revenues increased by 24.5% to $241.8 million compared to Q1 2022.

Product revenues grew by 25.2% to $237.8 million compared to Q1 2022, driven by increased test volumes.

Approximately 626,200 tests were processed, including 607,700 tests accessioned in Natera's laboratory.

The company reported a net loss of $136.9 million, or ($1.23) per diluted share.

Total Revenue
$242M
Previous year: $194M
+24.5%
EPS
-$1.23
Previous year: -$1.45
-15.2%
Tests Processed
626.2K
Previous year: 489.3K
+28.0%
Tests Accessioned
607.7K
Previous year: 473.2K
+28.4%
Total Tests Reported
583.4K
Previous year: 456.1K
+27.9%
Gross Profit
$93.6M
Previous year: $90.9M
+3.0%
Cash and Equivalents
$812M
Previous year: $752M
+8.0%
Free Cash Flow
-$92.5M
Previous year: -$153M
-39.6%
Total Assets
$1.32B
Previous year: $1.14B
+15.2%

Natera

Natera

Forward Guidance

Natera is raising its expectations for 2023 total revenue from $980 million to $1.0 billion to a new range of $995 million to $1.015 billion, and continues to expect 2023 gross margin to be approximately 41% to 44% of revenues; selling, general and administrative costs to be approximately $510 million to $540 million; research and development costs to be $325 million to $345 million, and net cash consumption to be approximately $300 million to $325 million.